Age & Reason

Age & Reason

The 5 Key Planks of a Strategic Aging Policy

The Fiscal TimesAugust 26, 2014

When Janet Yellen speaks about the structural policy vs. the fiscal or monetary policy that's needed to fuel economic growth and job creation, she might also consider the developed countries of Japan and within Europe, which need the structural shift even more than we do in the U.S.  

Consider Japan’s diminished stature as an economic power, which has been evident for at least 20 years now. Abenomics isn’t making anything better. The economy shrunk by an annualized 6.8 percent in the second quarter. But this setback isn’t a momentary lapse; it's a deeply...

3 Positive Lessons from Robin Williams’s Untimely Death

The Fiscal TimesAugust 12, 2014

Robin Williams died far too young at age 63. In life, he showed us how to trample the ordinary by sounding his barbaric yawp from the rooftops of Hollywood. He taught us about being extraordinary and how not to let the conventions of yesterday rule our lives today and tomorrow.

The fact that we believe he died so young says a great deal about life in the 21st century. Billions of us are over age 60 is the mark of our time.

This is why...

The Wisdom of Marketing to Aging Boomers

The Fiscal TimesJuly 21, 2014

As Procter & Gamble Co. takes new aim at aging Americans by making and marketing products for adults suffering from incontinence, the move confirms one thing: While good public policy can help transform the billion of us over age 60 by 2020 into a source of economic growth – it is markets that will do the trick.

It makes perfect sense that P&G engages in this arena as we observe the huge explosion of market opportunities in Japan, which is both the...

A New Way to Tackle the Worst Killer Diseases

The Fiscal TimesJuly 12, 2014

Amid the unbearable heat in D.C., some fresh news comes from the House Energy and Commerce Committee hearings. Their 21st Century Cures Initiative is showing real, visionary leadership in solving some of the most urgent problems in health and medicine: regulatory reform, stronger intellectual property, and more effective clinical trials. If they get that right, it will also have huge positive consequences for economic growth,...

America Follows Japan's Lead on Aging at Our Peril

The Fiscal TimesJune 17, 2014

As the U.S. continues to grapple with immigration reform, especially in this midterm election cycle, there are lessons to be learned from one of the most xenophobic nations on the planet: Japan.

In the last few weeks the Japanese Prime Minister, Shinzo Abe, has made clear he’ll continue to oppose any real immigration for Japan. While Abe can be applauded for...

The Fed Needs to Get Educated About Aging

The Fiscal TimesMay 27, 2014

New York Fed Chair William C. Dudley, one of the top decision-makers at the central bank, last week delivered an economic speech that The Financial Times called “upbeat.” During his speech, however, he singled out the aging of the population as a “significant headwind” to the U.S.’s economic potential.

There’s a...

Pfizer Backlash Proves Politicians Don’t Get It

The Fiscal TimesMay 20, 2014

Pfizer’s move to acquire British-based pharma company AstraZeneca has proven that too many in the political world don’t have a clue how markets work; don’t know how innovation takes place; and don’t understand how economic growth is achieved.

The U.K. Parliament has grilled Pfizer CEO Ian Read, asking him to make promises about...

Is Hillary Too Old to Run? Not on Your Life

The Fiscal TimesMay 18, 2014

There will be plenty of reasons to vote against Hillary in 2016 if she becomes the Democratic nominee for the presidency, but her age will not be one of them.  

Brain injury or not, the relationship between aging and health as a factor in Hillary’s decision to run, and how well she might govern, is legitimate, though probably for exactly the opposite reasons most assume. Her age of just about 75 at the end of a first term would put her roughly at the...

Time to Upgrade our Pharma Companies for a New Century

The Fiscal TimesApril 24, 2014

The pharmaceutical sector is still treading water in its search to find an operating model that will work in the 21st century. The shocking news of GlaxoSmithKline’s sale of its cancer-drug business to Novartis – and the many recent huge deals like it – are the most recent evidence.

It’s time to lump pharma in with music, television, energy, and banking as mega-industries in profound states of change....

The IMF Needs to Answer An Age-Old Question

The Fiscal TimesApril 8, 2014

As International Monetary Fund officials and central bankers gather in D.C. this week for their annual meeting, we’re still debating if we should intervene in countries and financial institutions that face economic and fiscal crisis.

At the center of this debate is the role of the IMF, which was recently fought over in Congress and connected to the issue of shifting funds from crisis to general accounts and other matters of voting...